Blue Jet Healthcare Limited (BLUEJET) AI Stock Analysis

• Market Cap: ₹67.30B
• Dividend Yield: 0.22%
• Average Volume (3M): 19.19K
• Price to Earnings (P/E): 57.2
• Beta (1Y): 0.96
• Revenue Growth: 63.34%
• EPS Growth: 109.89%
• Country: IN
• Employees: 447
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.30
• Shares Outstanding: 173,465,420
• 10 Day Avg. Volume: 15,409
• 30 Day Avg. Volume: 19,187
• PEG Ratio: 0.55
• Price to Book (P/B): 12.87
• Price to Sales (P/S): 14.16
• P/FCF Ratio: -427.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 19.32
• Revenue Forecast (FY): ₹12.26B

• Rating: 65 Neutral
• Price Target: ₹382.00 ▼(-41.54% Downside)
• Action: Reiterated Date: 02/14/26
• Date: Action: Reiterated 02/14/26

The score is driven primarily by strong financial performance (growth, margins, and a low-debt balance sheet), tempered by weak free cash flow generation. Technical indicators are the main near-term risk due to a pronounced downtrend despite oversold conditions, while valuation appears moderate with a low dividend yield.

Positive Factors

Revenue Growth

A 45% revenue jump to ₹10,299M in 2025 demonstrates durable demand and successful market penetration in API markets. Sustained top-line growth supports scale economics, reinvestment in capacity and specialty molecules, and long-term revenue visibility from B2B contracts.

Profitability & Margins

Elevated gross and net margins plus strong EBIT/EBITDA margins point to a high-margin product mix and efficient manufacturing. Persistent margin strength enhances resilience to input cost swings and supports sustainable internal funding for R&D and quality/compliance investments.

Strong Balance Sheet

Extremely low leverage and a high equity ratio provide financial flexibility to fund capex, absorb shocks, and pursue growth without heavy external financing. High ROE shows effective capital deployment, supporting durable shareholder returns potential over time.

Negative Factors

Negative Free Cash Flow

A swing to negative FCF is a material structural concern: it constrains the company’s ability to self-fund capex, working capital and strategic projects. Persistent negative FCF could force external financing or slow investments despite strong accounting profits.

Weak Cash Conversion

A 0.15 operating cash flow to net income ratio shows earnings are not translating into cash efficiently. This can reflect higher receivables, inventory or payment-term pressure; if durable, it undermines liquidity and makes earnings less reliable for funding needs.

Customer Disclosure / Concentration Risk

Lack of disclosed major-customer or segment detail masks potential customer concentration. In a B2B contract manufacturing model, reliance on a few large pharma clients can create outsized revenue risk if contracts are lost or volumes shift, increasing business volatility.

Blue Jet Healthcare Limited Business Overview & Revenue Model

Company Description

Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for applications in pharmaceutical and healthcare products. It provides integrated contrast media intermediates, saccharin and related salts, and niche pharmaceutical intermediates and APIs, as well as CDMO/CMO and development services. Blue Jet Healthcare Limited has operations in India, Norway, the United States, Sweden, Italy, Spain, and internationally. The company was incorporated in 1968 and is headquartered in Thane, India.

How the Company Makes Money

BLUEJET generates revenue through multiple streams, including the sale of pharmaceutical products and medical devices to hospitals, clinics, and healthcare providers. The company also engages in long-term contracts with healthcare institutions for the supply of essential medical supplies, which provides a stable revenue base. Additionally, BLUEJET may collaborate with research organizations and healthcare providers to develop new products, often securing funding or revenue-sharing agreements as part of these partnerships. The company's focus on innovation allows it to stay competitive in the market, driving sales through both direct product offerings and strategic partnerships.

Blue Jet Healthcare Limited Financial Statement Overview

Summary

Strong revenue growth and profitability (Income Statement score 85) plus a very stable, low-leverage balance sheet (Balance Sheet score 82) are partially offset by weak cash conversion and negative free cash flow in 2025 (Cash Flow score 72).

Income Statement

Blue Jet Healthcare has demonstrated strong financial performance with significant growth in total revenue from ₹7,103 million in 2024 to ₹10,299 million in 2025, reflecting a robust revenue growth rate of 45.01%. The gross profit margin improved to 55.24% in 2025, indicating efficient cost management. The net profit margin also increased to 29.65%, reflecting higher profitability. EBIT and EBITDA margins are solid at 49.30% and 41.18%, respectively. Overall, the income statement shows excellent growth and profitability.

Balance Sheet

The balance sheet of Blue Jet Healthcare reveals strong financial health with a low debt-to-equity ratio of 0.02, indicating minimal leverage. The equity ratio stands at 79.94%, showcasing a high level of financial stability. Return on equity (ROE) is impressive at 26.93%, reflecting effective use of equity to generate profits. The company's significant equity base and low debt level highlight its stability and low risk.

Cash Flow

Blue Jet Healthcare's cash flow performance is mixed. The operating cash flow to net income ratio is 0.15, suggesting lower cash conversion efficiency. However, the free cash flow to net income ratio is negative due to the decrease in free cash flow from ₹669 million in 2024 to -₹341 million in 2025, indicating challenges in generating free cash flow. While the company maintains positive operating cash flow, the pressure on free cash flow presents a potential area of concern.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	12.22B	10.30B	7.10B	7.18B	6.77B	4.94B
Gross Profit	6.32B	5.69B	3.89B	2.70B	2.97B	2.47B
EBITDA	4.88B	4.24B	2.48B	2.43B	2.69B	2.15B
Net Income	3.59B	3.05B	1.64B	1.60B	1.82B	1.38B
Balance Sheet
Total Assets	0.00	14.18B	10.59B	8.62B	7.13B	5.36B
Cash, Cash Equivalents and Short-Term Investments	3.06B	3.06B	3.09B	2.55B	1.81B	979.70M
Total Debt	0.00	199.86M	16.13M	68.31M	228.39M	516.15M
Total Liabilities	-11.33B	2.84B	2.14B	1.81B	1.92B	1.96B
Stockholders Equity	11.33B	11.33B	8.45B	6.81B	5.22B	3.40B
Cash Flow
Free Cash Flow	0.00	-341.15M	669.59M	822.79M	1.21B	807.67M
Operating Cash Flow	0.00	457.65M	2.41B	1.42B	1.46B	1.30B
Investing Cash Flow	0.00	-351.83M	-2.64B	-1.47B	-760.26M	-566.48M
Financing Cash Flow	0.00	-185.57M	-19.86M	-42.33M	-561.45M	-221.90M

Blue Jet Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 653.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 653.45 is above the 20-day moving average (MA) of 397.91, above the 50-day MA of 452.76, and below the 200-day MA of 665.69, indicating a bearish trend. The MACD of -18.13 indicates Negative momentum. The RSI at 38.75 is Neutral, neither overbought nor oversold. The STOCH value of 56.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.

Blue Jet Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	75 Outperform	₹50.26B	30.45	―	0.13%	14.35%	15.79%
CONCORDBIO	66 Neutral	₹125.79B	54.58	―	0.80%	3.63%	-1.21%
BLUEJET	65 Neutral	₹67.30B	57.24	―	0.22%	63.34%	109.89%
BIOCON	63 Neutral	₹626.03B	91.56	―	0.12%	10.62%	-66.88%
JUBLINGREA	61 Neutral	₹89.91B	59.25	―	0.74%	3.80%	64.94%
SYNGENE	61 Neutral	₹162.61B	439.86	―	0.19%	8.57%	-2.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Blue Jet Healthcare Limited Corporate Events

Blue Jet Healthcare to Build New Manufacturing Facility in Andhra Pradesh

Blue Jet Healthcare Limited has announced a groundbreaking ceremony for a new manufacturing facility at the Industrial Park Rambilli Cluster Phase II in Anakapalli district, Andhra Pradesh, scheduled for February 28, 2026. The project forms part of the company’s broader growth strategy to expand its production footprint and enhance infrastructure in response to rising market demand.

By adding this new site in Andhra Pradesh, Blue Jet Healthcare aims to improve its ability to meet growing customer requirements and strengthen its operational capacity. The expansion is expected to support the company’s long-term positioning in the healthcare manufacturing space and could reinforce its competitiveness as demand in key markets continues to increase.